Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030742 | 0.89 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL7033698 | 0.87 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL7036244 | 0.85 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL7039001 | 0.84 | CYP11B2 (0.43) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL7030643 | 0.83 | DHODH (0.44) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL7075155 | 0.81 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL1907548 | 0.79 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL7034038 | 0.77 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL7039905 | 0.77 | ALDH1A1 (0.52) | MAPK14MAPK13MAPK12MAPK11ALDH1A1 | |
| SCHEMBL7036392 | 0.76 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289958-A2 | BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) | Leo Pharma A/S (DK) | 2003-03-12 | — | — | EP | claimed |
| US-6432962-B2 | Benzophenones as inhibitors of IL-1β and TNF-α | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-08-13 | — | — | US | claimed |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-07 | — | — | US | claimed |
| WO-2001090074-A2 | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-11-29 | — | — | WO | claimed |
| EP-1289958-A2 | BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) | Leo Pharma A/S (DK) | 2003-03-12 | — | — | EP | disclosed |
| US-6432962-B2 | Benzophenones as inhibitors of IL-1β and TNF-α | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-08-13 | — | — | US | disclosed |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| WO-2001090074-A2 | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | IL1B, IL1A, NFKBIA | MAPK14 625/4885MAPK13 1908/4885MAPK12 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.